SCHEMBL6208739

SCHEMBL6208739

COc1ccc2c(c1)c(O)cc(=O)n2C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 4/20 0.53
HPGD P15428 4/20 0.53
HSD17B10 Q99714 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MEN1 O00255 1/20 0.53
HTT P42858 1/20 0.53
KMT2A Q03164 1/20 0.53
NPSR1 Q6W5P4 3/20 0.50
BCHE P06276 2/20 0.50
ACHE P22303 2/20 0.50
RET P07949 1/20 0.49
THRB P10828 1/20 0.48
APAF1 O14727 1/20 0.47
PABPC1 P11940 1/20 0.47
PKM P14618 1/20 0.47
IDO1 P14902 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8184169 0.87 ALDH1A1 (0.59) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL30507409 0.87 ALDH1A1 (0.59) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL1001961 0.82 NQO2 (0.59) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL9287885 0.82 KDM4E (0.43) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL6206973 0.82 MAPT (0.43) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL829534 0.81 MAPT (0.53) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL15099945 0.79 ALDH1A1 (0.58) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL2266978 0.78 KDM4E (0.51) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL8366206 0.77 KDM4E (0.55) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL25269828 0.77 KDM4E (0.50) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921821-B2 Antagonists of melanin concentrating hormone receptor ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
EP-1534703-A2 ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR ABBOTT LABORATORIES (US) 2005-06-01 EP disclosed
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MILLENNIUM PHARMACEUTICALS, INC. 2004-06-03 US disclosed
WO-2003106452-A2 ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-12-24 WO disclosed
US-6143766-A ENZYME INHIBITORS WITH IMIDAZOLE GROUPS WARNER-LAMBERT COMPANY (US) 2000-11-07 US disclosed
US-3968119-A OPTICAL BRIGHTENERS BAYER AKTIENGESELLSCHAFT (DT) 1976-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MCHR1, MCHR2, MC1R MAPT 4185/4885SMN1; SMN2 4051/4885ALDH1A1 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.